个性化治疗推荐中联合预测标志物方法的比较
该研究比较了三种参数化方法(回归方法、Kraemer方法及其改进方法)在随机试验数据中联合多个生物标志物以制定个性化治疗推荐的效果。通过蒙特卡洛模拟和FINE试验数据应用,发现回归方法在所有模拟场景中均优于Kraemer方法,改进方法除强未观测预后标志物情况外也能改善推荐。所有方法对参数模型误设敏感。
要点
- 回归方法在联合多个标志物制定个性化治疗推荐时优于Kraemer方法。
- 改进的Kraemer方法利用预后评分匹配样本,多数情况下改善推荐。
- 所有方法对参数模型误设敏感,需谨慎验证模型假设。
核心结论
- Kraemer提出的方法在联合多个生物标志物方面并不优于回归方法。
- 所有方法均对参数模型的误设敏感。
研究设计与样本
- 研究描述了三种参数化方法:回归方法、Kraemer方法及其利用预后评分匹配的改进方法。
- 使用蒙特卡洛模拟在多个数据生成模型下比较这些方法,并应用于FINE随机试验数据。
主要发现
- 回归方法在所有数据生成场景中均优于Kraemer方法。
- 改进的Kraemer方法除存在强未观测预后标志物的情况外,能改善治疗推荐。
- 在FINE试验示例中,回归方法的个性化治疗推荐算法显示弱改善。
临床怎么用
- 在制定个性化治疗推荐时,可优先考虑回归方法联合多个生物标志物。
- 使用参数化方法时需注意模型误设风险,并进行敏感性分析。
局限性
- 所有方法对参数模型误设敏感。
- 改进的Kraemer方法在强未观测预后标志物存在时效果受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the presence of heterogeneous treatment effects, it is desirable to divide patients into subgroups based on their expected response to treatment. This is formalised via a personalised treatment recommendation: an algorithm that uses biomarker measurements to select treatments. It could be that multiple, rather than single, biomarkers better predict these subgroups. However, finding the optimal combination of multiple biomarkers can be a difficult prediction problem. METHODS: We described three parametric methods for finding the optimal combination of biomarkers in a personalised treatment recommendation, using randomised trial data: a regression approach that models outcome using treatment by biomarker interactions; an approach proposed by Kraemer that forms a combined measure from individual biomarker weights, calculated on all treated and control pairs; and a novel modification of Kraemer's approach that utilises a prognostic score to sample matched treated and control subjects. Using Monte Carlo simulations under multiple data-generating models, we compare these approaches and draw conclusions based on a measure of improvement under a personalised treatment recommendation compared to a standard treatment. The three methods are applied to data from a randomised trial of home-delivered pragmatic rehabilitation versus treatment as usual for patients with chronic fatigue syndrome (the FINE trial). Prior analysis of this data indicated some treatment effect heterogeneity from multiple, correlated biomarkers. RESULTS: The regression approach outperformed Kraemer's approach across all data-generating scenarios. The modification of Kraemer's approach leads to improved treatment recommendations, except in the case where there was a strong unobserved prognostic biomarker. In the FINE example, the regression method indicated a weak improvement under its personalised treatment recommendation algorithm. CONCLUSIONS: The method proposed by Kraemer does not perform better than a regression approach for combining multiple biomarkers. All methods are sensitive to misspecification of the parametric models.
引用
- Pierce M, Emsley R. A comparison of approaches for combining predictive markers for personalised treatment recommendations. Trials. 2021. PMID: 33407760. doi:10.1186/s13063-020-04901-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。